Common Stock, $0.0001 par value per share
- Symbol
- GLUE
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.07 · 8-K
Monte Rosa Therapeutics, Inc.
GLUENASDAQEQUITYCurrent
Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to Vote of Security Holders On June 11, 2026, Monte Rosa Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 16, 2026, the record date for the Annual Meeting, there were 84,382,573 outstanding shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”).…
Company context
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology, and neurology. For more information, visit www.monterosatx.com.
Current securities
Recent company filings
Registered securities in this filing
MONTE ROSA THERAPEUTICS, INC. · 8-K · Filed 2026-06-11
Disclosure sections
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07. Submission of Matters to Vote of Security Holders
On June 11, 2026, Monte Rosa Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 16, 2026, the record date for the Annual Meeting, there were 84,382,573 outstanding shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). The Company’s stockholders voted on the following matters, which are described in detail in the Company’s definitive proxy statement on Schedule 14A (the “Proxy Statement”): (i) to elect three directors, Andrew Schiff, M.D., Chandra P. Leo, M.D. and Anthony Manning, Ph. D., as Class II directors of the Company, each to serve for a three-year term expiring at the Company’s 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, subject to their earlier death, resignation or removal and (ii) to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Proposal 1 - Election of Class II Director Nominees
The stockholders of the Company elected Andrew Schiff, M.D., Chandra P. Leo, M.D. and Anthony Manning, Ph. D. as Class II directors of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2029 and until their successors have been duly elected and qualified or until their earlier resignation or removal. The results of the stockholders’ vote with respect to the election of the Class II directors were as follows:
Votes Votes Broker
For Withheld Non-Votes
──────────────────────────────────────────────────────────────────────────
Andrew Schiff, M.D. 71,409,008 741,197 3,128,885
Chandra P. Leo, M.D. 71,469,933 680,272 3,128,885
Anthony Manning, Ph. D. 56,995,916 15,154,289 3,128,885
Proposal 2 - Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm
The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders’ vote with respect to such ratification were as follows:
Votes Votes Broker
For Against Abstain Non-Votes
───────────────────────────────────────────────────────
75,171,524 57,950 49,616 0
No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.